Search

Author/Creator Bloor, A.

1. BRENTUXIMAB VEDOTIN FOR RELAPSED HODGKIN LYMPHOMA AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION: a RETROSPECTIVE STUDY OF THE EBMT LYMPHOMA WORKING PARTY. (June 2017)

Authors:
Bazarbachi, A.; Boumendil, A.; Finel, H.; Mohty, M.; Castagna, L.; Blaise, D.; Peggs, K.; Afanasyev, B.; Diez‐Martin, J.; Corradini, P.; Socié, G.; Robinson, S.; Gutiérrez‐García, G.; Bonifazi, F.; Yakoub‐Agha, I.; Gülbas, Z.; Bloor, A.; Delage, J.; Esquirol, A.; Malladi, R.
Journal:
Hematological oncology
Issue:
Volume 35(2017)Supplement 2
Page Start:
83
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Long‐term outcome of patients receiving haematopoietic allogeneic stem cell transplantation as first transplant for high‐risk Hodgkin lymphoma: a retrospective analysis from the Lymphoma Working Party‐EBMT. (8th November 2021)

Authors:
Gutiérrez‐García, G.; Martínez, C.; Boumendil, A.; Finel, H.; Malladi, R.; Afanasyev, B.; Tsoulkani, A.; Wilson, K. M. O.; Bloor, A.; Nikoloudis, M.; Richardson, D.; López‐Corral, L.; Castagna, L.; Cornelissen, J.; Giltat, A.; Collin, M.; Fanin, R.; Bonifazi, F.; Robinson, S.; Montoto, S.
Journal:
British journal of haematology
Issue:
Volume 196:Number 4(2022)
Page Start:
1018
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. P1459: SAFETY AND EFFICACY FINDINGS OF AUTO1, A FAST-OFF RATE CD19 CAR, IN RELAPSED/REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA (B-NHL), AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) / SMALL LYMPHOCYTIC LYMPHOMA (SLL). (23rd June 2022)

Authors:
Roddie, C.; Dias, J.; O'Reilly, M.; Mitsikakou, M.; Charalambous, E.; Green, L.; Vaughan, M.; Agliardi, G.; Garcia, J.; Lewin, E.; Lowdell, M.; Marzolini, M.; Wood, L.; Holmes, H.; Ngai, Y.; Popova, B.; Wilson, W.; Kunaseelan, S.; Spanswick, V.; Lowe, H.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
1341
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. P673: DEPLETION AND RECOVERY OF NORMAL B-CELLS DURING AND AFTER TREATMENT WITH CHEMOIMMUNOTHERAPY, IBRUTINIB OR VENETOCLAX. (23rd June 2022)

Authors:
Rawstron, A.; Webster, N.; Pitchford, A.; Dalal, S.; Bloor, A.; de Tute, R.; Hockaday, A.; Jackson, S.; Cairns, D.; Greatorex, N.; Allsup, D.; Munir, T.; Hillmen, P.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
571
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. S145: THE COMBINATION OF IBRUTINIB PLUS VENETOCLAX RESULTS IN A HIGH RATE OF MRD NEGATIVITY IN PREVIOUSLY UNTREATED CLL: THE RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE PHASE III NCRI FLAIR TRIAL. (23rd June 2022)

Authors:
Hillmen, P.; Pitchford, A.; Bloor, A.; Pettitt, A.; Patten, P.; Forconi, F.; Schuh, A.; Fox, C.; Elmusharaf, N.; Gatto, S.; Kennedy, B.; Gribben, J.; Pemberton, N.; Sheehy, O.; Preston, G.; Howard, D.; Hockaday, A.; Cairns, D.; Jackson, S.; Greatorex, N.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
46
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗